Human adult bone-marrow derived somatic cell therapy - Neuronyx

Drug Profile

Human adult bone-marrow derived somatic cell therapy - Neuronyx

Alternative Names: hABM-SC therapy - Neuronyx; Human adult stem cell therapy - Neuronyx; NX CP105

Latest Information Update: 16 Aug 2011

Price : $50

At a glance

  • Originator Neuronyx
  • Class Cardiovascular therapies; Eye disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Myocardial infarction; Retinal disorders; Stroke; Wounds

Most Recent Events

  • 16 Dec 2016 Biomarkers information updated
  • 16 Aug 2011 Discontinued - Phase-I for Myocardial infarction in USA (Intracoronary)
  • 16 Aug 2011 Discontinued - Preclinical for Retinal disorders in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top